Altamira Therapeutics Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Altamira Therapeutics Ltd (CYTO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Altamira Therapeutics Ltd vs Its Competitors
- Peer differentiation: Revenue per employee of $-0.02M compares with $1.02M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Altamira Therapeutics Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Altamira Therapeutics Ltd | - | - | - | - |
| Competitors combined (157) | ||||
| High-Confidence Competitors (13) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CYTO Stock Performance relative to its Competitors
CYTO Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Moderna Inc | 282.9% | Outperformed |
| 3 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 4 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 5 | Anaptysbio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Altamira Therapeutics Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Altamira Therapeutics Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Altamira Therapeutics Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Altamira Therapeutics Ltd | 1.35 | -0.77 |
| Eli Lilly And Company | 1,034,082.40 | 79,665.80 |
| Johnson and Johnson | 645,992.07 | 97,929.00 |
| Beone Medicines Ltd | 550,872.13 | 6,128.24 |
| Abbvie Inc | 463,275.89 | 64,386.00 |
| Merck and Co Inc | 359,088.60 | 66,569.00 |
| SUBTOTAL | 5,213,309.49 | 850,878.59 |
Sign in to see all competitors of Altamira Therapeutics Ltd .
Sources: Altamira Therapeutics Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Altamira Therapeutics Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Altamira Therapeutics Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Feldan Bio Inc. | Named by the company | 85% |
| Marinomed Biotech AG | Named by the company | 85% |
| Procter & Gamble | Named by the company | 85% |
| Sound Pharmaceuticals | Named by the company | 85% |
| Amgen | Named by the company | 85% |
| Bio-Path Holdings, Inc. | Named by the company | 85% |
| Dyne Therapeutics Inc. | Named by the company | 85% |
| GSK | Named by the company | 85% |
| Otonomy | Named by the company | 85% |
| SaNOtize Research and Development Corp. | Named by the company | 85% |
| Abbvie | Named by the company | 85% |
| Avidity Biosciences, Inc. | Named by the company | 85% |
| Dicerna Pharmaceuticals, Inc. | Named by the company | 85% |
| Genentech | Named by the company | 85% |
| Nasaleze Ltd. | Named by the company | 85% |
| Reckitt Benckiser | Named by the company | 85% |
| Washington University | Named by the company | 85% |
| Andros Pharmaceuticals Co., Ltd. | Named by the company | 85% |
| BMS | Named by the company | 85% |
| Entrada Therapeutics Inc. | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| Ovensa Inc. | Named by the company | 85% |
| Sirnaomics Ltd. | Named by the company | 85% |
| Acuitas Therapeutics Inc. | Named by the company | 85% |
| Bayer | Named by the company | 85% |
| Duet BioTherapeutics Inc. | Named by the company | 85% |
| Genevant Sciences Corp. | Named by the company | 85% |
| Nasus Pharma Ltd. | Named by the company | 85% |
| Sanofi | Named by the company | 85% |
| Aro Biotherapeutics | Named by the company | 85% |
| Chimeron Bio Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Altamira Therapeutics Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Altamira Therapeutics Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Altamira Therapeutics Ltd .
Altamira Therapeutics Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Altamira Therapeutics Ltd | 1 | -24,168 | -264,305 |
| Eli Lilly And Company | 1,034,082 | 1,593,316 | 534,224 |
| Johnson and Johnson | 645,992 | 695,518 | 149,411 |
| Beone Medicines Ltd | 550,872 | 510,686 | 54,642 |
| Abbvie Inc | 463,276 | 1,129,579 | 110,807 |
| Merck and Co Inc | 359,089 | 887,587 | 42,267 |
| PEERS TOTAL | 5,213,308 | 1,021,802 | 140,440 |
Sign in to see all peers for Altamira Therapeutics Ltd .
Altamira Therapeutics Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Altamira Therapeutics Ltd .
Altamira Therapeutics Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Altamira Therapeutics Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Altamira Therapeutics Ltd ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,060,478 | 19.39 % |
| 2 | Johnson and Johnson | 652,141 | 11.92 % |
| 3 | Beone Medicines Ltd | 560,341 | 10.24 % |
| 4 | Abbvie Inc | 468,722 | 8.57 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Altamira Therapeutics Ltd | - | 0.00 % |
Market cap and industry share for the rest of Altamira Therapeutics Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-04-01.
Altamira Therapeutics Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Altamira Therapeutics Ltd's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Altamira Therapeutics Ltd's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Altamira Therapeutics Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of tracked competitors (42.60 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Altamira Therapeutics Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Altamira Therapeutics Ltd | 0.86 | 1.32 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Sign in to see all peers for Altamira Therapeutics Ltd .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Altamira Therapeutics Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Altamira Therapeutics Ltd | Q4 2023 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +10.2 % | -2.9 % |
Sign in to see all peers for Altamira Therapeutics Ltd .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Altamira Therapeutics Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Altamira Therapeutics Ltd | Q4 2023 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sign in to see all peers for Altamira Therapeutics Ltd .
Altamira Therapeutics Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Altamira Therapeutics Ltd | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
Sign in to see all peers for Altamira Therapeutics Ltd .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Altamira Therapeutics Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Altamira Therapeutics Ltd | - | - |
| Eli Lilly And Company | 38.84 | 12.98 |
| Johnson and Johnson | 30.64 | 6.60 |
| Beone Medicines Ltd | 831.68 | 89.89 |
| Abbvie Inc | 73.90 | 7.20 |
| Merck and Co Inc | 117.24 | 5.39 |
| PEERS AVERAGE | 44.58 | 6.13 |
Sign in to see all peers for Altamira Therapeutics Ltd .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.